Complete regression of metastatic malignant melanoma endoscopically after nivolumab administration

Código QR

Complete regression of metastatic malignant melanoma endoscopically after nivolumab administration

Guardado en:

Detalles Bibliográficos
Autores principales:	Dae Gon Ryu, Cheol Woong Choi, Su Jin Kim, Dae Hwan Kang, Su Bum Park
Formato:	article
Lenguaje:	EN
Publicado:	The Korean Association of Internal Medicine 2021
Materias:	Medicine R
Acceso en línea:	https://doaj.org/article/7dc520d21483412b82de2f0ffe3d1c67
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Autoimmune hemolytic anemia during long‐term administration of nivolumab for metastatic melanoma
por: Koji Nakajima, et al.
Publicado: (2021)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Alexander N Shoushtari, et al.
Publicado: (2021)

Spontaneous Regression of Primary Melanoma and Multiple Melanocytic Nevi in a Patient With Metastatic Melanoma
por: Giovanni Paolino, et al.
Publicado: (2020)

Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review
por: Ammar Haikal, et al.
Publicado: (2018)

Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab
por: Kiyoshi Minohara, et al.
Publicado: (2021)

Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
por: Pramod Savarapu, et al.
Publicado: (2021)

BRAF Mutation Status in Primary, Recurrent, and Metastatic Malignant Melanoma and Its Relation to Histopathological Parameters
por: Aris Spathis, et al.
Publicado: (2019)

THE EFFECT OF NIVOLUMAB IN PEDIATRIC MALIGNANT TUMORS: A SINGLE CENTER EXPERIENCE WITH EIGHT PATIENTS
por: Veysel GOK, et al.
Publicado: (2021)

Endoscopic semiotics of metastatic bronchial tumors
por: Anna Y. Kontsevaya, et al.
Publicado: (2021)

Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab
por: Tian Zhang, et al.
Publicado: (2021)

Maculopapular erythema caused by previously used chemotherapy drugs after nivolumab treatment for malignant mesothelioma
por: Junko Kanai, et al.
Publicado: (2021)

Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study
por: Romualdo Barroso-Sousa, et al.
Publicado: (2021)

Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study
por: Morten Fink, et al.
Publicado: (2021)

Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
por: Hiroto Yoneda, et al.
Publicado: (2021)

Treatment of Advanced Metastatic Melanoma
por: Pietro Quaglino, et al.
Publicado: (2021)

Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma
por: Matthew D. Tucker, et al.
Publicado: (2021)

Raman-guided subcellular pharmaco-metabolomics for metastatic melanoma cells
por: Jiajun Du, et al.
Publicado: (2020)

Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
por: Toshiki Kijima, et al.
Publicado: (2021)

Arginine deprivation therapy for malignant melanoma
por: Yoon JK, et al.
Publicado: (2012)

Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis
por: Huo Geng-wei, et al.
Publicado: (2021)

Correction: Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
Publicado: (2021)

Primary cilium depletion typifies cutaneous melanoma in situ and malignant melanoma.
por: Jinah Kim, et al.
Publicado: (2011)

Multiregional genetic evolution of metastatic uveal melanoma
por: Daniel A. Rodriguez, et al.
Publicado: (2021)

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
por: Nobukazu Fujimoto, et al.
Publicado: (2021)

Regression of nevi in a melanoma patient treated with interferon
por: Ayelet Rishpon, et al.
Publicado: (2012)

Nivolumab-Induced Exocrine Pancreatic Insufficiency
por: Boudewijn Sweep, et al.
Publicado: (2021)

Molecular profiling of driver events in metastatic uveal melanoma
por: Joakim Karlsson, et al.
Publicado: (2020)

Metastatic melanoma to the ovary in pregnancy: A case report
por: D.S. Huang, et al.
Publicado: (2021)

The Role of HGF/MET Signaling in Metastatic Uveal Melanoma
por: Ryota Tanaka, et al.
Publicado: (2021)

Microenvironment-derived factors driving metastatic plasticity in melanoma
por: Isabella S. Kim, et al.
Publicado: (2017)

PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
por: Naoya Maekawa, et al.
Publicado: (2021)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
por: Katsuhiro Yoshimura, MD, PhD, et al.
Publicado: (2021)

Use of nivolumab for colon cancer with Lynch syndrome
por: G. A. Khakimov, et al.
Publicado: (2020)

The effect of 4-hexylresorinol administration on NAD+ level and SIRT activity in Saos-2 cells
por: In-Song Lee, et al.
Publicado: (2021)

Involvement of ANXA5 and ILKAP in susceptibility to malignant melanoma.
por: Yoana Arroyo-Berdugo, et al.
Publicado: (2014)

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
por: Shahneen Sandhu, et al.
Publicado: (2021)

Metastatic and non-metastatic melanoma imaging using Sgc8-c aptamer PTK7-recognizer
por: Estefanía Sicco, et al.
Publicado: (2021)

Prognostic Values of G-Protein Mutations in Metastatic Uveal Melanoma
por: Mizue Terai, et al.
Publicado: (2021)

The Effect of Intraocular Pressure-Lowering Medication on Metastatic Uveal Melanomas
por: Jan Pals, et al.
Publicado: (2021)

Metastatic melanoma with sebocyte-like melanocytes and widespread visceral involvement
por: Li-Wei Chang, et al.
Publicado: (2020)